Connect
MJA
MJA

Cost-effectiveness of screening for bowel cancer

Terry D Bolin, Melvyn G Korman, Fiona Nicholson, Lynne Pezzullo, Jeffrey Engelman, Katherine Collings and David Gilchrist Creelman
Med J Aust 2016; 204 (1): 11-12. || doi: 10.5694/mja15.00037
Published online: 18 January 2016

Increasing bowel cancer testing rates through a general practitioner-organised health care package would reduce incidence and prove cost-effective

Treating bowel cancer is expensive, and the cost is rising rapidly. In the past decade, costs have increased for treating cancers at all stages (in particular, Stages 3 and 4), largely due to increased chemotherapy options and the introduction of more effective but expensive drug regimens.1 Increased treatment costs are a stimulus for the considerable effort in the areas of prevention and early detection.

  • Terry D Bolin1
  • Melvyn G Korman2
  • Fiona Nicholson2
  • Lynne Pezzullo3
  • Jeffrey Engelman4
  • Katherine Collings5
  • David Gilchrist Creelman3

  • 1 Gastrointestinal and Liver Clinic, Sydney, NSW
  • 2 Monash Health, Melbourne, VIC
  • 3 Deloitte Access Economics, Canberra, ACT
  • 4 St George Private Hospital, Sydney, NSW
  • 5 The Gut Foundation, Sydney, NSW

Correspondence: kerrie@terrybolin.com

Competing interests:

No relevant disclosures.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.